Peptifact

KPV Dosage: Most of the Research Is About How to Deliver It, Not What a Dose Does

KPV has 48 indexed papers and no trial registration. We classified them: the largest group by far is drug-delivery engineering — hydrogels, nanoparticles, iontophoresis — because getting a tripeptide to the tissue is the unsolved problem.

Robert F · Edited by Caroline S · Published 2026-09-11

Illustration: Laboratory glassware and a clear hydrogel on a white lab bench, emphasizing delivery methods.
Illustration

KPV's file has an unusual centre of gravity. There are 48 indexed papers, a clean mechanism and a decade and a half of serious work — and the largest single group of those papers is not about what the compound does. It is about how to get it to the tissue at all.

This page reports what the sources state and does not recommend anything. Our page on the questions we ask of any dosage figure sets out what separates a label figure from a convention. How brands appear on this site is set out on our disclosure page.

What the molecule is

KPV is lysine-proline-valine: three amino acids, and specifically the last three residues of alpha-melanocyte-stimulating hormone — written in the literature as alpha-MSH(11-13).

The research premise, examined directly in a 2003 paper in the Journal of Pharmacology and Experimental Therapeutics that set out to dissect the anti-inflammatory effect of the core and C-terminal regions, is that this fragment carries much of the parent hormone's anti-inflammatory activity without its pigmentation effects. That is why a tripeptide has a literature at all.

What does not exist

  • DailyMed: zero records on 2026-09-11. No approved product, so no labelled dose, route or maximum.
  • ClinicalTrials.gov: no studies. No protocol or results record exists for any human administration.
  • PubMed randomised-controlled-trial filter: zero.

Classifying all 48

A title-and-abstract search returned 66 records for KPV[tiab] and 48 once restricted to a peptide, tripeptide, colitis, inflammation or alpha-MSH context — the rest are unrelated abbreviation collisions in stress-physiology and receptor papers. We retrieved and read all 48.

Group Approx. count What they are
Drug-delivery engineering 14 Hyaluronic-acid nanoparticles, mucoadhesive and double-network hydrogels, temperature-sensitive gels, transdermal iontophoresis, film dressings, PepT1-targeted nanodrugs, self-immolative oral conjugates
alpha-MSH biology and reviews 12 The parent hormone's immune role, melanocortin-system reviews, tripeptide biochemistry
Gut and colitis models 8 Murine colitis, PepT1 uptake, colitis-associated cancer, mucosal barrier restoration
Skin, wound and cornea 7 Corneal epithelial wound healing, keratinocyte studies, diabetic wound dressings, tripeptide wound-healing reviews
Immune and cellular mechanism 5 Basophil activation, bronchial epithelial cells, candidacidal activity, TNF-alpha signalling
Chemistry and analysis 2 Structural modification by glycoalkylation, a stability-indicating HPLC assay
Registered human trials 0 —

There is more published work on how to deliver KPV than on what any quantity of it does. That is not a rhetorical framing; it is what reading 48 titles produces.

Why delivery dominates

The reason is in the file's mechanistic anchor. A 2008 Gastroenterology paper reported that KPV is taken up through PepT1, the intestinal peptide transporter, and that this uptake reduces intestinal inflammation. Once the effect depends on a specific transporter in a specific tissue, the route of administration stops being an implementation detail and becomes the experiment.

Everything downstream follows from that. The 2010 Gastroenterology paper used drug-loaded nanoparticles in a polysaccharide hydrogel targeted to the colon. The 2017 Molecular Therapy paper used hyaluronic-acid-functionalised nanoparticles for oral delivery. The 2022 Acta Biomaterialia paper built a KPV-binding double-network hydrogel to restore the gut mucosal barrier. A 2026 paper in Science Advances describes inflammation-triggered self-immolative conjugates specifically to overcome gastrointestinal barriers to oral peptide delivery.

A stated quantity with no vehicle attached omits the variable that most of this literature exists to solve.

The 36 "human" records, and what they actually are

PubMed's humans MeSH term matches 36 of the KPV records, which is the number most likely to be misread. Reading them shows what they are: human keratinocytes, human bronchial epithelial cells, human basophils, microporated human skin in a diffusion cell, human cell lines.

A humans tag marks human-derived material, not human administration. The randomised-trial filter returning zero, and the registry holding no study, is the check that settles it.

What the sources state as a quantity

Figure stated Route Where it comes from
250–500 µg per day Subcutaneous Vendor and protocol pages; no stated origin
~500 µg to 1 mg per day Oral capsule Vendor pages; no stated origin
0.5–1% preparations Topical Compounding and vendor pages; no stated origin

No source we located states where any of these came from, and none names a study. Given that the published work is dominated by engineered vehicles, a figure quoted for a plain solution or a plain capsule is describing a preparation the literature has largely not tested.

The arithmetic, if a figure is being converted

A 5 mg vial in 2 mL of bacteriostatic water gives 2.5 mg/mL. A stated 500 µg is 0.2 mL — 20 units on a U-100 insulin syringe. The same vial in 1 mL gives 5 mg/mL and halves that to 10 units.

Our reconstitution page carries the arithmetic for other vial-and-volume combinations, and our guide to the U-100 unit scale covers what the unit markings mean.

What is not established

  • No approved label anywhere, so no dose has been reviewed by a regulator.
  • No trial registration anywhere, so no human protocol or result exists to check a claim against.
  • No randomised trial in the indexed literature.
  • No stated origin for any circulating figure, in any of the three routes.
  • The animal evidence is a mouse gut model. Induced murine colitis appears across the 2008, 2010, 2016, 2022 and 2024 papers. It is a coherent model and it is a mouse.
  • The delivery question is open in the literature itself. Researchers were still publishing new vehicles in 2026 to get the tripeptide past the gastrointestinal tract, which is a direct statement that the simple routes are not solved.

What a reader can check in five minutes

  1. Search DailyMed for KPV — zero records.
  2. Search ClinicalTrials.gov for KPV — no studies.
  3. Run KPV[tiab] in PubMed, then add AND randomized controlled trial[pt] and watch it return nothing.
  4. Read the 48 titles and count how many name a hydrogel, a nanoparticle or a delivery system.
  5. Check whether any figure on a vendor page states which vehicle it applies to.

KPV is also the fourth peptide in the premixed blend covered on what a KLOW vial's ratio means for each component. Our BPC-157 page reports the same evidence shape for a different gut-associated peptide — strong rodent model, no registered human trial. How to read a dosing claim sets out the checks that catch an untraceable figure, and our page on reading a certificate of analysis covers what a research-market document establishes about what is in a vial.

Sources and dates

Opened 2026-09-11: the DailyMed SPL search API for KPV peptide (zero records); the ClinicalTrials.gov v2 API for KPV (no studies); PubMed through the NCBI E-utilities for KPV[tiab] (66 records), for KPV[tiab] AND (peptide[tiab] OR tripeptide[tiab] OR colitis[tiab] OR inflammation[tiab] OR "alpha-MSH"[tiab]) (48 records), for the same query with the humans MeSH term (36 records) and with the randomised-controlled-trial publication type (zero), with all 48 summaries retrieved and classified by hand into the groups in the table above. Papers named in the text — the 2003 Journal of Pharmacology and Experimental Therapeutics dissection of the core and C-terminal fragments, the 2008 Gastroenterology PepT1 paper, the 2010 Gastroenterology colon-targeted nanoparticle paper, the 2017 Molecular Therapy hyaluronic-acid nanoparticle paper, the 2022 Acta Biomaterialia hydrogel paper and the 2026 Science Advances self-immolative conjugate paper — are all in that retrieved record set. Corrections go to the contact page.

Frequently asked questions

What is the standard KPV dose?

There is no standard in any regulatory or clinical sense: no approved label, no trial registration, and no randomised trial in the indexed literature to borrow a figure from. Figures circulate for oral capsules, subcutaneous injection and topical preparations. None that we located names a source. This page reports that absence rather than filling it, and notes that a quantity stated without its delivery vehicle leaves out what most of the published research is about.

What is KPV?

Lysine-proline-valine — three amino acids, and specifically the C-terminal three residues of alpha-melanocyte-stimulating hormone, written as alpha-MSH(11-13). The research interest is that this short fragment appears to carry a substantial part of the parent hormone's anti-inflammatory activity without the pigmentation effects, a question a 2003 paper in the Journal of Pharmacology and Experimental Therapeutics set out to dissect directly.

Why is so much of the research about hydrogels and nanoparticles?

Because delivery is the compound's actual problem. A 2008 Gastroenterology paper established that KPV enters intestinal cells through the peptide transporter PepT1, which makes the route of administration decisive rather than incidental. Fourteen of the 48 indexed papers are consequently formulation work — hyaluronic-acid nanoparticles, mucoadhesive and double-network hydrogels, temperature-sensitive gels, transdermal iontophoresis across microporated human skin, film dressings, and in 2026 a self-immolative oral conjugate designed to survive the gastrointestinal tract. The research community's effort has gone into the vehicle, which is a fair signal about what the hard part is.

PubMed says 36 records are human-tagged. Aren't those human studies?

No, and this is the most common misreading of a PubMed count. The humans MeSH term marks work involving human-derived material, which includes cell lines, primary keratinocytes, bronchial epithelial cells, basophils and excised skin. Reading the 36 titles shows that is what they are. The randomised-controlled-trial filter returns zero and the registry holds no study, which is the check that resolves it. A human tag is not a human trial.

Is KPV related to BPC-157 or the other gut peptides?

Only by subject matter. KPV is a fragment of alpha-melanocyte-stimulating hormone and acts, in the published work, through PepT1 uptake and melanocortin-pathway signalling; the mechanisms and the literatures are separate. What they share is the pattern this catalogue keeps finding: a promising rodent model, a well-developed mechanism, and no registered human trial. Our BPC-157 page reports the same shape for a different molecule.

What does a stated milligram figure look like in a syringe?

It depends on the reconstitution. A 5 mg lyophilized vial in 2 mL of bacteriostatic water gives 2.5 mg/mL, so a stated 500 micrograms is 0.2 mL — 20 units on a U-100 insulin syringe. The same vial in 1 mL doubles the concentration and halves that to 10 units. The arithmetic is on our reconstitution page. It is worth noting that most of the published KPV work does not use a plain solution at all, so the conversion answers a narrower question than it appears to.